JRJoseph M. Ronda

Joseph M. Ronda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph M. Ronda has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

    by Hilary A. Uyhelji, Scott J. Nicholson, Thomas E. Nesthus, Julia L. Beckel, Elizabeth B. Klerman, Charles A. Czeisler, Robin K. Yuan, Arturo Arrona-Palacios, Pamela Song, Joseph M. Ronda, et al.

    Background: Inter-individual variation in response to insufficient or altered timing of sleep presents a challenge for the development of personalized approaches to fatigue monitoring and mitigation. Insufficient sleep has adverse health impacts, can result in impaired neurobehavioral performance, and can substantially increase the risk of injury and even mortality in safety–critical operations such as transportation. The present study provides a detailed exploration of physiological, neurobehavioral, and gene expression changes during sleep restriction, acute total sleep deprivation, and altered timing of sleep among 59 healthy volunteer participants who completed a 10-day inpatient study. Results: Reducing the quantity or altering the timing of sleep significantly impacts self-reported estimates of sleep duration, polysomnography-recorded sleep stages, and neurobehavioral performance test results. Impaired neurobehavioral performance was associated with transcriptomic changes in gene expression. A comparison of current and prior research on total sleep deprivation indicated that reproducible candidate gene expression biomarkers exist for at least one metric of attention, specifically, Psychomotor Vigilance Test (PVT) lapses. Conclusions: Candidate biomarkers of fatigue-related impairment were identified that responded to single neurobehavioral performance endpoints, as well as those that responded to multiple types or metrics of performance. Reproducible identification of biomarker candidates for PVT lapses during total sleep deprivation increases confidence in the ability to develop a molecular approach to fatigue-related impairment detection, while novel discoveries expanded the list of candidate genes to other impairment metrics. Molecular biomarkers for neurobehavioral performance impairment represent a potentially valuable tool to more precisely monitor the neurobehavioral performance deficits resulting from sleep loss, and further research and validation could eventually augment fatigue risk management practices that historically emphasize scheduling and rest opportunities. The data generated from self-assessment, polysomnography, neurobehavioral performance, and molecular investigations provide a wealth of information made publicly available for further data mining and scientific advancements. Trial registration: ClinicalTrials.gov, TRN: NCT04211506, Registered 23 December 2019.


  • High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults

    by Jeanne F. Duffy, Wei Wang, Joseph M. Ronda, Charles A. Czeisler

    Aging is associated with changes in sleep, and improving sleep may have important consequences for the health, cognition, and quality of life of older adults. Many prescription sleep aids increase the risk of nighttime falls, have adverse effects on next‐day cognition, and are associated with increased mortality. Melatonin, a hormone secreted at night, increases sleep duration in young adults but only when administered during the day when endogenous levels are low. In a month‐long cross‐over study, we randomized 24 healthy older (age >55, mean 64.2 ± 6.3 years) participants to receive 2 weeks of placebo and 2 weeks of either a low (0.3 mg) or high (5.0 mg) dose of melatonin 30 min before lights out. Sleep was polysomnographically recorded and was scheduled during both the biological day and night using a forced desynchrony design. Although 0.3 mg melatonin had a trend towards increasing sleep efficiency (SE) overall, this was due to its effects on sleep during the biological day. In contrast, 5 mg melatonin significantly increased SE during both biological day and night, mainly by increasing the duration of Stage 2 non‐rapid eye movement sleep and slightly shortening awakenings. Melatonin should be further explored as a sleep aid for older adults.


  • A new face of sleep: The impact of post-learning sleep on recognition memory for face-name associations

    by Leonie Maurer, Kirsi-Marja Zitting, Kieran Elliott, Charles A. Czeisler, Joseph M. Ronda, Jeanne F. Duffy


  • Sleep and cognitive function of crewmembers and mission controllers working 24-h shifts during a simulated 105-day spaceflight mission

    by Laura K. Barger, Kenneth P. Wright, Tina M. Burke, Evan D. Chinoy, Joseph M. Ronda, Steven W. Lockley, Charles A. Czeisler